Company Overview of Ferring Holding SA
Ferring Holding SA, through its subsidiaries, develops, manufactures, and markets pharmaceutical products in the fields of reproductive health, urology, gastroenterology, endocrinology, and osteoarthritis. It offers MINIRIN for bedwetting in children and nocturia in adults; FIRMAGON for advanced hormone-dependent prostate cancer; and TESTIM for treating men suffering from low testosterone. The company also provides MENOPUR and BRAVELLE ovarian-stimulating treatments used in the preparation for in-vitro fertilization; TRACTOCILE to treat pre-term labor; ZOMACTON, a recombinant human growth hormone used to treat growth failure in children; PENTASA for the treatment of inflammatory bowel diseas...
Chemin de la Vergognausaz 50
Founded in 2000
Key Executives for Ferring Holding SA
Executive Chairman and Chief Executive Officer
President of the Executive Board and Chief Operating Officer
President of Ferring Pharmaceuticals Inc. and COO of Ferring Pharmaceuticals Inc.
Compensation as of Fiscal Year 2017.
Ferring Holding SA Key Developments
Ferring Holding SA Presents at Pre-Filled Syringes San Diego Summit, Jun-05-2017 through Jun-06-2017
Jun 3 17
Ferring Holding SA Presents at Pre-Filled Syringes San Diego Summit, Jun-05-2017 through Jun-06-2017. Venue: HYATT REGENCY MISSION BAY, 1441 Quivira Road, San Diego, California, United States. Presentation Date & Speakers: Jun-05-2017, Tina Rees, Associate Director - Human Factors. Jun-06-2017, Tina Rees, Associate Director - Human Factors.
Ferring Pharmaceuticals Announces Management Changes
Apr 4 17
Ferring Pharmaceuticals announced that Dominic Moorhead has been appointed as Executive Vice President and Chief Financial Officer, effective July 1, 2017. Moorhead succeeds Peter Wilden. Following a three-month transition period, Moorhead will assume full responsibility for the Finance, Corporate Information Systems and Internal Audit functions of the global Ferring Group. Wilden will continue to represent Ferring on a number of additional Boards. Moorhead has 30 years' finance and business experience in the life sciences industry. For the past year, he has been a strategic advisor to executives and investors in biotech.
Targeted Immuno Therapies and Ferring Sign IBD Treatment Collaboration Agreement
Jan 15 16
Ferring (Switzerland) and Targeted Immuno Therapies have entered into a strategic collaboration agreement whereby the Swiss firm received the global rights, with the exception of China, to the discovery of a novel treatment for inflammatory bowel diseases (IBD), with the parties set to collaborate on the development of a technology created by the Swedish firm. As per the agreement, Ferring would finance further product development and clinical trial programmes.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|